{"transactions":[{"id":2172963,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-26T16:06:10.000Z","date":"2022-08-25","kind":"purchase","acquired":true,"shares":11600,"price":1.6499,"value":19138.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents a weighted average purchase price. Actual purchase prices ranged from $1.6499 to $1.65 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0000899243-22-029840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924322029840/doc4.xml","form_type":"4"}},{"id":2172962,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-26T16:06:10.000Z","date":"2022-08-24","kind":"purchase","acquired":true,"shares":18400,"price":1.6467,"value":30299.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents a weighted average purchase price. Actual purchase prices ranged from $1.638 to $1.649 per share. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares purchased within the range indicated."}],"balance_after":28400,"source":{"system":"sec-edgar","filing":"0000899243-22-029840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924322029840/doc4.xml","form_type":"4"}},{"id":2251541,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-05-31T16:06:04.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of May 26, 2023, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service."}],"balance_after":15000,"derivative":{"exercise_price":1.61,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0000899243-22-020150","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924322020150/doc4.xml","form_type":"4"}},{"id":2350045,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Interim CEO, COO & CFO"}}],"security":"Common Stock","published_at":"2022-03-04T17:55:40.000Z","date":"2022-03-03","kind":"grant","acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents grant of Restricted Stock Units (the \"RSU Award\") payable solely in common stock of the Issuer.  The shares subject to the RSU Award shall vest in equal quarterly installments over two years, with 1/8th of the total number of shares subject to the RSU Award vesting on each quarterly anniversary of the date of grant."}],"balance_after":265000,"source":{"system":"sec-edgar","filing":"0001209191-22-016440","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919122016440/doc4.xml","form_type":"4"}},{"id":2443467,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-05T17:05:49.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in equal monthly installments, at a rate of 1/48th of the total number of shares on each monthly anniversary of the date of grant, such that the total number of shares shall be fully vested on the four-year anniversary of the date of grant."}],"balance_after":125000,"derivative":{"exercise_price":13.39,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-22-001788","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919122001788/doc4.xml","form_type":"4"}},{"id":2510387,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-16T20:17:52.000Z","date":"2021-11-16","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022."}],"balance_after":103294,"derivative":{"exercise_price":2.23,"expiration_date":"2028-11-27","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-064924","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121064924/doc4.xml","form_type":"4"}},{"id":2510386,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-11-16T20:17:52.000Z","date":"2021-11-16","kind":"exercise","acquired":true,"shares":30000,"price":2.23,"value":66900.0,"ownership":{"direct":true},"balance_after":90000,"source":{"system":"sec-edgar","filing":"0001209191-21-064924","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121064924/doc4.xml","form_type":"4"}},{"id":2546268,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-10-07T18:24:12.000Z","date":"2021-10-05","kind":"exercise","acquired":false,"shares":4963,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to the option shall vest and become exercisable monthly over four years."}],"balance_after":95037,"derivative":{"exercise_price":54.85,"expiration_date":"2030-02-05","underlying":"Common Stock","underlying_shares":4963},"source":{"system":"sec-edgar","filing":"0001209191-21-059984","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121059984/doc4.xml","form_type":"4"}},{"id":2546267,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-10-07T18:24:12.000Z","date":"2021-10-05","kind":"sale","acquired":false,"shares":4963,"price":98.5,"value":488855.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001209191-21-059984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121059984/doc4.xml","form_type":"4"}},{"id":2546266,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-10-07T18:24:12.000Z","date":"2021-10-05","kind":"exercise","acquired":true,"shares":4963,"price":54.85,"value":272220.55,"ownership":{"direct":true},"balance_after":64963,"source":{"system":"sec-edgar","filing":"0001209191-21-059984","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121059984/doc4.xml","form_type":"4"}},{"id":2597622,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-18T17:25:23.000Z","date":"2021-08-17","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022."}],"balance_after":133294,"derivative":{"exercise_price":2.23,"expiration_date":"2028-11-27","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-052277","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121052277/doc4.xml","form_type":"4"}},{"id":2597621,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-18T17:25:23.000Z","date":"2021-08-16","kind":"exercise","acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vested as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022."}],"balance_after":163294,"derivative":{"exercise_price":2.23,"expiration_date":"2028-11-27","underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001209191-21-052277","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121052277/doc4.xml","form_type":"4"}},{"id":2597620,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T17:25:23.000Z","date":"2021-08-17","kind":"exercise","acquired":true,"shares":30000,"price":2.23,"value":66900.0,"ownership":{"direct":true},"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001209191-21-052277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121052277/doc4.xml","form_type":"4"}},{"id":2597619,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T17:25:23.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":2077,"price":98.9,"value":205415.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-21-052277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121052277/doc4.xml","form_type":"4"}},{"id":2597618,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T17:25:23.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":1100,"price":97.28,"value":107008.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.89 to $97.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":32077,"source":{"system":"sec-edgar","filing":"0001209191-21-052277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121052277/doc4.xml","form_type":"4"}},{"id":2597617,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T17:25:23.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":2330,"price":96.32,"value":224425.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.68 to $96.62, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":33177,"source":{"system":"sec-edgar","filing":"0001209191-21-052277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121052277/doc4.xml","form_type":"4"}},{"id":2597616,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T17:25:23.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":7335,"price":95.02,"value":696971.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.66 to $95.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":35507,"source":{"system":"sec-edgar","filing":"0001209191-21-052277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121052277/doc4.xml","form_type":"4"}},{"id":2597615,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T17:25:23.000Z","date":"2021-08-16","kind":"sale","acquired":false,"shares":9158,"price":94.23,"value":862958.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.63 to $94.63, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":42842,"source":{"system":"sec-edgar","filing":"0001209191-21-052277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121052277/doc4.xml","form_type":"4"}},{"id":2597614,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-08-18T17:25:23.000Z","date":"2021-08-16","kind":"exercise","acquired":true,"shares":22000,"price":2.23,"value":49060.0,"ownership":{"direct":true},"balance_after":52000,"source":{"system":"sec-edgar","filing":"0001209191-21-052277","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121052277/doc4.xml","form_type":"4"}},{"id":2650292,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T18:59:14.000Z","date":"2021-06-30","kind":"purchase","acquired":true,"shares":3600,"price":12.66,"value":45576.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-21-026816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924321026816/doc4.xml","form_type":"4"}},{"id":2650291,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T18:59:14.000Z","date":"2021-06-29","kind":"purchase","acquired":true,"shares":6400,"price":12.59,"value":80576.0,"ownership":{"direct":true},"balance_after":6400,"source":{"system":"sec-edgar","filing":"0000899243-21-026816","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924321026816/doc4.xml","form_type":"4"}},{"id":2649668,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-30T17:46:35.000Z","date":"2021-06-30","kind":"exercise","acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022."}],"balance_after":185294,"derivative":{"exercise_price":2.23,"expiration_date":"2028-11-27","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-21-044027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121044027/doc4.xml","form_type":"4"}},{"id":2649667,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-06-30T17:46:35.000Z","date":"2021-06-28","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option will vest as to 25% of the shares on November 15, 2019, with the remaining 75% of shares vesting in equal monthly installments beginning on December 15, 2019 and ending on November 15, 2022."}],"balance_after":215594,"derivative":{"exercise_price":2.23,"expiration_date":"2028-11-27","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-044027","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121044027/doc4.xml","form_type":"4"}},{"id":2649666,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-30T17:46:35.000Z","date":"2021-06-30","kind":"exercise","acquired":true,"shares":30000,"price":2.23,"value":66900.0,"ownership":{"direct":true},"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-21-044027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121044027/doc4.xml","form_type":"4"}},{"id":2649665,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-30T17:46:35.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":1044,"price":56.16,"value":58631.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $55.73 to $56.71, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-044027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121044027/doc4.xml","form_type":"4"}},{"id":2649664,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-30T17:46:35.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":4153,"price":55.11,"value":228871.83,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $54.66 to $55.36, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":1044,"source":{"system":"sec-edgar","filing":"0001209191-21-044027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121044027/doc4.xml","form_type":"4"}},{"id":2649663,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-30T17:46:35.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":7079,"price":54.13,"value":383186.27,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $53.64 to $54.61, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":5197,"source":{"system":"sec-edgar","filing":"0001209191-21-044027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121044027/doc4.xml","form_type":"4"}},{"id":2649662,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-30T17:46:35.000Z","date":"2021-06-28","kind":"sale","acquired":false,"shares":7724,"price":53.39,"value":412384.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $52.64 to $53.63, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":12276,"source":{"system":"sec-edgar","filing":"0001209191-21-044027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121044027/doc4.xml","form_type":"4"}},{"id":2649661,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-30T17:46:35.000Z","date":"2021-06-28","kind":"exercise","acquired":true,"shares":20000,"price":2.23,"value":44600.0,"ownership":{"direct":true},"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001209191-21-044027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121044027/doc4.xml","form_type":"4"}},{"id":2712524,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-05-14T17:23:59.000Z","date":"2021-05-13","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of May 13, 2022, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service."}],"balance_after":20000,"derivative":{"exercise_price":16.34,"expiration_date":"2031-05-12","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-21-019560","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924321019560/doc4.xml","form_type":"4"}},{"id":2866374,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"COO & Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-02-11T20:00:51.000Z","date":"2021-02-09","kind":"grant","acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares subject to the Option shall vest and become exercisable on each monthly anniversary of the vesting start date (and if there is no corresponding day, the last day of the month)."}],"balance_after":40000,"derivative":{"exercise_price":46.1,"expiration_date":"2031-02-08","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001209191-21-009920","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919121009920/doc4.xml","form_type":"4"}},{"id":2931532,"issuer":{"id":84409,"kind":"organization","name":"Vincerx Pharma, Inc.","symbol":"VINC"},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-12-28T21:27:39.000Z","date":"2020-12-23","kind":"grant","acquired":true,"shares":6667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of December 23, 2021, the next annual meeting of stockholders or the consummation of a change of control, subject to the director's continued service."}],"balance_after":6667,"derivative":{"exercise_price":19,"expiration_date":"2030-12-23","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000899243-20-035394","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1796129/000089924320035394/doc4.xml","form_type":"4"}},{"id":2944238,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-15T19:04:41.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"50% of the shares will vest on March 31, 2023 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 1 (as defined below) has been met, and 50% of the shares will vest on March 31, 2024 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 2 (as defined below) has been met; provided further that, in each case, the grantee will have been continuously a service provider from the date of grant through each such vesting date. Performance Condition No. 1 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2023 has exceeded $135 per share. Performance Condition No. 2 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2024 has exceeded $170 per share."}],"balance_after":100000,"derivative":{"exercise_price":29.6,"expiration_date":"2030-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-20-063601","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919120063601/doc4.xml","form_type":"4"}},{"id":2944237,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-15T19:04:41.000Z","date":"2020-12-11","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date, subject to the grantee's continuous service to the Issuer on each such date."}],"balance_after":100000,"derivative":{"exercise_price":29.6,"expiration_date":"2030-12-10","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-20-063601","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919120063601/doc4.xml","form_type":"4"}},{"id":3145250,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-05-18T14:13:47.000Z","date":"2020-05-14","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the total number of shares subject to this option will vest and become exercisable on each monthly anniversary of the vesting start date, beginning March 29, 2020."}],"balance_after":30000,"derivative":{"exercise_price":45.88,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-030020","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919120030020/doc4.xml","form_type":"4"}},{"id":3281895,"issuer":{"id":7403,"kind":"organization","name":"Quince Therapeutics, Inc."},"owners":[{"id":124229,"kind":"person","name":"LOWE CHRISTOPHER P.","position":1,"cik":"0001376260","reported_name":"LOWE CHRISTOPHER P.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-10T18:09:56.000Z","date":"2020-02-06","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of the shares subject to the option shall vest and become exercisable monthly over four years."}],"balance_after":100000,"derivative":{"exercise_price":54.85,"expiration_date":"2030-02-05","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-20-008065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1376260/000120919120008065/doc4.xml","form_type":"4"}}]}